THARIMMUNE INC (THAR)

Company Profile

Tharimmune Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The firm's pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.

Company Info

THARIMMUNE INC

1200 Route 22 East

Bridgewater NEW JERSEY

P: 13027432995

Employees: 1

Website: https://tharimmune.com/